Walter, Panretin activates all six known receptors (3 RARs and 3 RXRs) while Targretin activates the three RXRs and LGD1550 activates the three RARs, so theoretically, Panretin could have any applications for any of the above as well as the commercial products, Retin-A, Renova, or Accutane, which act through RARs.
At the present time topical Targretin is in trials for CTCL and Actinic Keratosis and of course Retin-A, Renova, and Accutane are topical treatments for acne, psoriasis, and wrinkles.
Interstingly, for psoriasis, LGND chose to initiate clinical trials using the oral formulation (for both Panretin and Targretin). For off label use of the topical formulation of Panretin however, I suspect that significant use would require some initial clinical data, and to my knowledge, topical Panretin is only being used to treat KS. |
